Cohbar (CWBR) | Financial Analysis & Statements
Cohbar Inc Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2023Income Metrics
Revenue
0
Operating Income
-4.4M
Net Income
-4.3M
EPS (Diluted)
$-1.49
Balance Sheet Metrics
Total Assets
12.5M
Total Liabilities
3.0M
Shareholders Equity
9.5M
Debt to Equity
0.32
Cash Flow Metrics
Operating Cash Flow
-3.2M
Free Cash Flow
-1.8M
Revenue & Profitability Trend
Cohbar Income Statement From 2018 to 2022
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Goods Sold | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Gross Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses | |||||
| Research & Development | 5.9M | 7.7M | 6.9M | 6.6M | 10.0M |
| Selling, General & Administrative | 6.5M | 7.7M | 6.3M | 6.0M | 5.3M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 12.4M | 15.4M | 13.2M | 12.6M | 15.3M |
| Operating Income | -12.4M | -15.4M | -13.2M | -12.6M | -15.3M |
| Operating Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Non-Operating Items | |||||
| Interest Income | 223.3K | 5.6K | 41.1K | 290.3K | 185.6K |
| Interest Expense | 10.2K | 73.2K | 815.9K | 752.1K | 557.1K |
| Other Non-Operating Income | - | - | -2.3M | - | - |
| Pre-tax Income | -12.2M | -15.5M | -16.3M | -13.0M | -15.7M |
| Income Tax | - | - | - | - | - |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -12.2M | -15.5M | -16.3M | -13.0M | -15.7M |
| Net Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Key Metrics | |||||
| EBITDA | -12.1M | -15.3M | -15.3M | -12.1M | -15.1M |
| EPS (Basic) | $-4.20 | $-6.90 | $-9.90 | $-9.00 | $-11.40 |
| EPS (Diluted) | $-4.20 | $-6.90 | $-9.90 | $-9.00 | $-11.40 |
| Basic Shares Outstanding | 2900202 | 2220981 | 1627145 | 1427220 | 1375147 |
| Diluted Shares Outstanding | 2900202 | 2220981 | 1627145 | 1427220 | 1375147 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Cohbar Balance Sheet From 2018 to 2022
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 5.9M | 5.0M | 2.9M | 12.6M | 5.7M |
| Short-term Investments | 9.8M | 21.3M | 18.1M | 0 | 16.5M |
| Accounts Receivable | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Other Current Assets | - | - | - | - | - |
| Total Current Assets | 16.2M | 26.9M | 21.4M | 12.9M | 22.4M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 412.7K | 860.4K | 860.4K | 839.8K | 727.4K |
| Goodwill | 18.1K | 19.3K | 18.1K | 19.2K | 20.2K |
| Intangible Assets | 18.1K | 19.3K | 18.1K | 19.2K | 20.2K |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 63.6K | 69.6K | 67.4K | 64.2K | 56.8K |
| Total Non-Current Assets | 147.2K | 349.5K | 479.5K | 607.1K | 597.8K |
| Total Assets | 16.4M | 27.3M | 21.9M | 13.5M | 23.0M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 180.1K | 372.0K | 727.6K | 444.8K | 1.1M |
| Short-term Debt | - | 366.3K | 349.3K | - | - |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | - | - | - | - | - |
| Total Current Liabilities | 1.0M | 1.7M | 3.1M | 2.0M | 2.2M |
| Non-Current Liabilities | |||||
| Long-term Debt | - | - | 348.8K | 3.4M | 2.9M |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | - | - | - | - | - |
| Total Non-Current Liabilities | 0 | 0 | 348.8K | 3.4M | 2.9M |
| Total Liabilities | 1.0M | 1.7M | 3.4M | 5.4M | 5.1M |
| Equity | |||||
| Common Stock | 2.9K | 2.9K | 61.1K | 43.1K | 42.6K |
| Retained Earnings | -96.9M | -84.7M | -69.3M | -53.0M | -39.9M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 15.3M | 25.6M | 18.5M | 8.1M | 18.0M |
| Key Metrics | |||||
| Total Debt | 0 | 366.3K | 698.2K | 3.4M | 2.9M |
| Working Capital | 15.2M | 25.3M | 18.4M | 10.9M | 20.3M |
Balance Sheet Composition
Cohbar Cash Flow Statement From 2018 to 2022
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -12.2M | -15.5M | -16.3M | -13.0M | -15.7M |
| Depreciation & Amortization | 99.2K | 140.9K | 156.7K | 147.7K | 79.1K |
| Stock-Based Compensation | 1.7M | 2.5M | 2.2M | 2.6M | 4.3M |
| Working Capital Changes | -45.9K | -529.1K | 282.8K | -698.0K | 815.2K |
| Operating Cash Flow | -10.4M | -13.3M | -10.8M | -10.6M | -10.1M |
| Investing Activities | |||||
| Capital Expenditures | 103.5K | -6.4K | -25.9K | -149.5K | -423.3K |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | -56.6M | -43.6M | -25.4M | -40.3M | -41.4M |
| Investment Sales | 68.1M | 40.5M | 7.3M | 56.8M | 30.5M |
| Investing Cash Flow | 11.5M | -3.1M | -18.2M | 16.3M | -11.3M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | - | - | - | 0 | 3.9M |
| Debt Repayment | -375.0K | -365.0K | 0 | - | 0 |
| Financing Cash Flow | -164.5K | 16.3M | 18.0M | 0 | 23.1M |
| Free Cash Flow | -10.4M | -14.5M | -9.8M | -10.3M | -10.6M |
| Net Change in Cash | 943.1K | -88.4K | -11.0M | 5.8M | 1.7M |
Cash Flow Trend
Cohbar Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-0.10
Forward P/E
-0.10
Price to Book
0.13
PEG Ratio
-0.10
Profitability Ratios
Profit Margin
0.00%
Operating Margin
0.00%
Return on Equity
-83.97%
Return on Assets
-48.31%
Financial Health
Current Ratio
4.16
Debt to Equity
0.00
Beta
1.38
Per Share Data
EPS (TTM)
$-4.37
Book Value per Share
$3.27
Revenue per Share
$0.00
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| CWBR | 1.2M | -0.10 | 0.13 | -83.97% | 0.00% | 0.00 |
| Vertex | 109.4B | 28.40 | 5.92 | 22.54% | 32.94% | 10.91 |
| Regeneron | 81.0B | 18.00 | 2.45 | 14.86% | 31.41% | 9.51 |
| Alnylam | 41.9B | 132.73 | 52.09 | 73.28% | 8.45% | 376.19 |
| Royalty Pharma plc | 29.4B | 27.89 | 3.29 | 13.20% | 32.42% | 92.33 |
| Insmed | 31.0B | -22.40 | 40.88 | -249.28% | -210.54% | 101.43 |
Financial data is updated regularly. All figures are in the company's reporting currency.